A Phase 2/3 interventional study of E/C/F/TAF and E/C/F/TAF (Low Dose) in Acquired Immune Deficiency Syndrome (AIDS) and HIV Infections, sponsored by Gilead Sciences. Completed at 16 sites in 5 countries. Open to participants aged 2 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-01-09.
Sponsored by Gilead Sciences · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies testing cobicistat in Acquired Immunodeficiency Syndrome — none open to participants now, 1 under way, 1 of them phase 3. Cobicistat · Acquired Immunodeficiency Syndrome.
Among the 16 studies testing cobicistat in Acquired Immunodeficiency Syndrome, this one is the 7th largest by enrollment, is one of 4 that started in 2013, is one of 2 in phase 2/3, and was the 6th registered.
3,038 studies on the registry are indexed under Acquired Immunodeficiency Syndrome; 308 are open to participants now.
Browse Acquired Immunodeficiency Syndrome studies →None of the 16 studies testing cobicistat in Acquired Immunodeficiency Syndrome is open now. The open studies under Acquired Immunodeficiency Syndrome, anywhere →
Cobicistat: first FDA approval 2012 (STRIBILD), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 198 Acquired Immunodeficiency Syndrome studies recruiting now, 118 (60%) set no upper age limit and 67 (34%) stop at 75 or younger; 43 take children under 18; 68 take healthy volunteers.
This study: 2 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 3 · Phase 3 7 · Phase 4 2
First in 2011; this study’s year is marked. 4 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 129 is above the median of 96 across 2,253 interventional studies indexed under Acquired Immunodeficiency Syndrome.
Median enrollment 116 across the 16 interventional studies. Of the 14 that completed or were terminated, 8 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 16 have an industry lead sponsor. The 8 most frequent:
Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
35 studies in Acquired Immunodeficiency Syndrome by Gilead Sciences: none open now, 1 under way, 1 of them phase 3. Of 34 finished, 19 (56%) have results posted.
Among the 35 studies in Acquired Immunodeficiency Syndrome by Gilead Sciences, this one is the 16th largest by enrollment of the 34 interventional ones that give a count, is one of 5 that started in 2013, is one of 4 in phase 2/3, and was the 30th registered.
Gilead Sciences’s Acquired Immunodeficiency Syndrome studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 16 studies testing cobicistat in Acquired Immunodeficiency Syndrome, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Gilead Sciences’s 35 in Acquired Immunodeficiency Syndrome:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objectives of Cohort 1 are to evaluate the steady state pharmacokinetics (PK) for elvitegravir (EVG) and tenofovir alafenamide (TAF) and confirm the dose of the elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) STR (Part A) and to evaluate the safety and tolerability of E/C/F/TAF STR through Week 24 (Part B) in human immunodeficiency virus - 1 (HIV-1) infected, antiretroviral (ARV) treatment-naive adolescents.
The primary objectives of Cohort 2 are to evaluate the PK of EVG and TAF (Part A), and to evaluate the safety and tolerability of E/C/F/TAF through Week 24 (Part B) in virologically suppressed HIV-1 infection children 6 to \< 12 years weighing >= 25 kg.
The primary objectives of Cohort 3 are to evaluate the PK of EVG and TAF and confirm the dose of the STR, and to evaluate the safety and tolerability of E/C/F/TAF low dose (LD) STR in virologically suppressed HIV-1 infected children ≥ 2 years of age and weighing ≥ 14 to \< 25 kg.
Key Inclusion Criteria:
Cohort 1
Cohort 2
Cohort 3
Key Exclusion Criteria:
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Treatment naive adolescents (12 to \< 18 years of age) living with human immunodeficiency virus (HIV) will receive E/C/F/TAF (150/150/200/10 mg) fixed-dose combination (FDC) once daily for 48 weeks. Participants who complete 48 weeks of study treatment will have the option to receive E/C/F/TAF in an extension phase of the study until: a) the participant turns 18 years old and E/C/F/TAF is commercially available for adults in the country in which the participant is enrolled; b) age-appropriate E/C/F/TAF become commercially available in the country in which the participant is enrolled; or c) Gilead elects to terminate development of E/C/F/TAF in that country.
Drug: E/C/F/TAF
Children (6 to \< 12 years of age weighing ≥ 25 kg) with HIV who were virologically suppressed will receive E/C/F/TAF (150/150/200/10 mg) FDC once daily for 48 weeks. Participants who complete 48 weeks of study treatment will have the option to receive E/C/F/TAF in an extension phase of the study until: a) the participant turns 18 years old and E/C/F/TAF is commercially available for adults in the country in which the participant is enrolled; b) age-appropriate E/C/F/TAF become commercially available in the country in which the participant is enrolled; or c) Gilead elects to terminate development of E/C/F/TAF in that country.
Drug: E/C/F/TAF
Children (≥ 2 years of age weighing ≥ 14 to \< 25 kg) with HIV who were virologically suppressed will receive E/C/F/TAF (90/90/120/6 mg) FDC once daily for 48 weeks. Participants who attain a weight of ≥ 25 kg during the course of the study will switch to adult E/C/F/TAF (150/150/200/10 mg) tablets administered orally, once daily with food. Participants who complete 48 weeks of study treatment will have the option to receive E/C/F/TAF in an extension phase of the study until: a) the participant turns 18 years old and E/C/F/TAF is commercially available for adults in the country in which the participant is enrolled; b) age-appropriate E/C/F/TAF became commercially available in the country in which the participant is enrolled; or c) Gilead elects to terminate development of E/C/F/TAF in that country.
Drug: E/C/F/TAF · Drug: E/C/F/TAF (Low Dose)
Drug pages: Elvitegravir · Cobicistat · Emtricitabine · Tenofovir alafenamide
Tablets administered orally with food.
Also known as: Genvoya®
Drug page: Tenofovir alafenamide
90/90/120/6 mg STR administered once daily orally with food.
Pharmacokinetic (PK) Parameter: AUCtau of Elvitegravir (EVG) (Cohort 1)
AUCtau is defined as concentration of drug over time (the area under the concentration versus time curve over the dosing interval).
Time frame: 0 (pre-dose, ≤ 30 minutes prior to dosing), 5 minutes, 0.25, 0.5, 1, 1.5, 2, 4, 5, 8 and 24 hours post-dose at Week 4
PK Parameter: AUCtau of EVG (Cohort 2)
AUCtau is defined as concentration of drug over time (the area under the concentration versus time curve over the dosing interval).
Time frame: 0 (pre-dose, ≤ 30 minutes prior to dosing), 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 8, and 24 hours post-dose at Week 4
PK Parameter: AUCtau of EVG (Cohort 3)
AUCtau is defined as concentration of drug over time (the area under the concentration versus time curve over the dosing interval).
Time frame: 0 (pre-dose, ≤ 30 minutes prior to dosing), 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, and 8 hours post-dose at Week 2
PK Parameter: AUClast of Tenofovir Alafenamide (TAF) (Cohort 1)
AUClast is defined as the concentration of drug from time zero to the last observable concentration, area under the concentration time curve to last observation (AUClast).
Time frame: 0 (pre-dose, ≤ 30 minutes prior to dosing), 5 minutes, 0.25, 0.5, 1, 1.5, 2, 4, 5, 8 and 24 hours post-dose at Week 4
PK Parameter: AUClast of TAF (Cohort 2)
AUClast is defined as the concentration of drug from time zero to the last observable concentration.
Time frame: 0 (pre-dose, ≤ 30 minutes prior to dosing), 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 8, and 24 hours post-dose at Week 4
PK Parameter: AUCtau of TAF (Cohort 3)
AUCtau is defined as concentration of drug over time (the area under the concentration versus time curve over the dosing interval).
Time frame: 0 (pre-dose, ≤ 30 minutes prior to dosing), 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, and 8 hours post-dose at Week 2
Cohort 1: Percentage of Participants With All Treatment-Emergent Adverse Events (AEs) and Treatment-Emergent Serious Adverse Events (SAEs)
Treatment-emergent adverse events (TEAEs) were defined as any AEs that begin or worsen on or after the start of study drug through 30 days after the last dose of study drug. The severity was graded based on the Gilead Sciences Grading Scale for Severity of Adverse Events. An AE that met one or more of the following outcomes was classified as serious: * Fatal * Life-threatening * Disabling/incapacitating * Results in hospitalization or prolongs a hospital stay * A congenital abnormality * Other important medical events may also be considered serious AEs if they may require medical or surgical intervention to prevent one of the outcomes listed above.
Time frame: From first dose date up to Week 24
Cohort 2: Percentage of Participants With All Treatment-Emergent AEs and Treatment-Emergent SAEs
TEAEs were defined as any AEs that begin or worsen on or after the start of study drug through 30 days after the last dose of study drug. The severity was graded based on the Gilead Sciences Grading Scale for Severity of Adverse Events. An AE that met one or more of the following outcomes was classified as serious: * Fatal * Life-threatening * Disabling/incapacitating * Results in hospitalization or prolongs a hospital stay * A congenital abnormality * Other important medical events may also be considered serious AEs if they may require medical or surgical intervention to prevent one of the outcomes listed above.
Time frame: From first dose date up to Week 24
Cohort 3: Percentage of Participants With All Treatment-Emergent AEs and Treatment-Emergent SAEs
TEAEs were defined as any AEs that begin or worsen on or after the start of study drug through 30 days after the last dose of study drug. The severity was graded based on the Gilead Sciences Grading Scale for Severity of Adverse Events. An AE that met one or more of the following outcomes was classified as serious: * Fatal * Life-threatening * Disabling/incapacitating * Results in hospitalization or prolongs a hospital stay * A congenital abnormality * Other important medical events may also be considered serious AEs if they may require medical or surgical intervention to prevent one of the outcomes listed above.
Time frame: From first dose date up to Week 24
PK Parameter: Ctau of EVG, Emtricitabine (FTC), Tenofovir (TFV), and Cobicistat (COBI) (Cohort 1)
Ctau is defined as the observed drug concentration at the end of the dosing interval.
Time frame: 0 (pre-dose, ≤ 30 minutes prior to dosing), 5 minutes, 0.25, 0.5, 1, 1.5, 2, 4, 5, 8 and 24 hours post-dose at Week 4
PK Parameter: Ctau of EVG, FTC, TFV and COBI (Cohort 2)
Ctau is defined as the observed drug concentration at the end of the dosing interval.
Time frame: (pre-dose, ≤ 30 minutes prior to dosing), 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 8, and 24 hours post-dose at Week 4
PK Parameter: Ctau of EVG, FTC, TFV, and COBI (Cohort 3)
Ctau is defined as the observed drug concentration at the end of the dosing interval.
Time frame: 0 (pre-dose, ≤ 30 minutes prior to dosing), 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, and 8 hours post-dose at Week 2
PK Parameter: Cmax of EVG, TAF, FTC, TFV, and COBI (Cohort 1)
Cmax is defined as the maximum concentration of drug.
Time frame: 0 (pre-dose, ≤ 30 minutes prior to dosing), 5 minutes, 0.25, 0.5, 1, 1.5, 2, 4, 5, 8 and 24 hours post-dose at Week 4
PK Parameter: Cmax of EVG, TAF, FTC, TFV, and COBI (Cohort 2)
Cmax is defined as the maximum concentration of drug.
Time frame: 0 (pre-dose, ≤ 30 minutes prior to dosing), 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 8, and 24 hours post-dose at Week 4
PK Parameter: Cmax of EVG, TAF, FTC, TFV, and COBI (Cohort 3)
Cmax is defined as the maximum concentration of drug.
Time frame: 0 (pre-dose, ≤ 30 minutes prior to dosing), 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, and 8 hours post-dose at Week 2
PK Parameter: CL/F of EVG and TAF (Cohort 1)
Apparent oral clearance (CL/F) is defined as the apparent clearance of the drug following oral administration.
Time frame: 0 (pre-dose, ≤ 30 minutes prior to dosing), 5 minutes, 0.25, 0.5, 1, 1.5, 2, 4, 5, 8 and 24 hours post-dose at Week 4
PK Parameter: CL/F of EVG and TAF (Cohort 2)
CL/F is defined as the apparent clearance of the drug following oral administration.
Time frame: 0 (pre-dose, ≤ 30 minutes prior to dosing), 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 8, and 24 hours post-dose at Week 4
PK Parameter: CL/F of EVG and TAF (Cohort 3)
CL/F is defined as the apparent clearance of the drug following oral administration.
Time frame: 0 (pre-dose, ≤ 30 minutes prior to dosing), 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, and 8 hours post-dose at Week 2
PK Parameter: Vz/F of EVG and TAF (Cohort 1)
Vz/F is defined as the apparent volume of distribution of the drug after oral administration.
Time frame: 0 (pre-dose, ≤ 30 minutes prior to dosing), 5 minutes, 0.25, 0.5, 1, 1.5, 2, 4, 5, 8 and 24 hours post-dose at Week 4
PK Parameter: Vz/F of EVG and TAF (Cohort 2)
Vz/F is defined as the apparent volume of distribution of the drug after oral administration.
Time frame: 0 (pre-dose, ≤ 30 minutes prior to dosing), 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 8, and 24 hours post-dose at Week 4
PK Parameter: Vz/F of EVG and TAF (Cohort 3)
Vz/F is defined as the apparent volume of distribution of the drug after oral administration.
Time frame: 0 (pre-dose, ≤ 30 minutes prior to dosing), 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, and 8 hours post-dose at Week 2
PK Parameter: AUCtau of FTC, TFV, and COBI (Cohort 1)
AUCtau is defined as concentration of drug over time (the area under the concentration versus time curve over the dosing interval).
Time frame: 0 (pre-dose, ≤ 30 minutes prior to dosing), 5 minutes, 0.25, 0.5, 1, 1.5, 2, 4, 5, 8 and 24 hours post-dose at Week 4
PK Parameter: AUCtau of FTC, TFV, and COBI (Cohort 2)
AUCtau is defined as concentration of drug over time (the area under the concentration versus time curve over the dosing interval).
Time frame: 0 (pre-dose, ≤ 30 minutes prior to dosing), 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 8, and 24 hours post-dose at Week 4
PK Parameter: AUCtau of FTC, TFV, and COBI (Cohort 3)
AUCtau is defined as concentration of drug over time (the area under the concentration versus time curve over the dosing interval).
Time frame: 0 (pre-dose, ≤ 30 minutes prior to dosing), 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, and 8 hours post-dose at Week 2
Cohort 1: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 24, as Defined by the FDA Snapshot Analysis
The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 24 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
Time frame: Week 24
Cohort 1: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 48, as Defined by the FDA Snapshot Analysis
The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
Time frame: Week 48
Cohort 1: Percentage of Participants With Plasma HIV-1 RNA < 400 Copies/mL at Week 24, as Defined by the FDA Snapshot Analysis
The percentage of participants with HIV-1 RNA \< 400 Copies/mL at Week 24 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
Time frame: Week 24
Cohort 1: Percentage of Participants With Plasma HIV-1 RNA < 400 Copies/mL at Week 48, as Defined by the FDA Snapshot Analysis
The percentage of participants with HIV-1 RNA \< 400 Copies/mL at Weeks 24 and 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
Time frame: Week 48
Cohort 2: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 24, as Defined by the FDA Snapshot Analysis
The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 24 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
Time frame: Week 24
Cohort 2: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 48, as Defined by the FDA Snapshot Analysis
The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
Time frame: Week 48
Cohort 3: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 24, as Defined by the FDA Snapshot Analysis
The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 24 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
Time frame: Week 24
Cohort 3: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 48, as Defined by the FDA Snapshot Analysis
The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
Time frame: Week 48
Cohort 1: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 24, Based on Missing = Failure Analyses
The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 24 was analyzed based on missing = failure analyses.
Time frame: Week 24
Cohort 1: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 48, Based on Missing = Failure Analyses
The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 48 was analyzed based on missing = failure analyses.
Time frame: Week 48
Cohort 1: Percentage of Participants With Plasma HIV-1 RNA < 400 Copies/mL at Week 24, Based on Missing = Failure Analyses
The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 24 was analyzed based on missing = failure analyses.
Time frame: Week 24
Cohort 1: Percentage of Participants With Plasma HIV-1 RNA < 400 Copies/mL at Week 48, Based on Missing = Failure Analyses
The percentage of participants with HIV-1 RNA \< 400 copies/mL at Week 48 was analyzed based on missing = failure analyses.
Time frame: Week 48
Cohort 2: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 24, Based on Missing = Failure Analyses
The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 24 was analyzed based on missing = failure analyses.
Time frame: Week 24
Cohort 2: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 48, Based on Missing = Failure Analyses
The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 48 was analyzed based on missing = failure analyses.
Time frame: Week 48
Cohort 2: Percentage of Participants With Plasma HIV-1 RNA < 400 Copies/mL at Week 24, Based on Missing = Failure Analyses
The percentage of participants with HIV-1 RNA \< 400 copies/mL at Week 24 was analyzed based on missing = failure analyses.
Time frame: Week 24
Cohort 2: Percentage of Participants With Plasma HIV-1 RNA < 400 Copies/mL at Week 48, Based on Missing = Failure Analyses
The percentage of participants with HIV-1 RNA \< 400 copies/mL at Week 48 was analyzed based on missing = failure analyses.
Time frame: Week 48
Cohort 3: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 24, Based on Missing = Failure Analyses
The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 24 was analyzed based on missing = failure analyses.
Time frame: Week 24
Cohort 3: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 48, Based on Missing = Failure Analyses
The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 48 was analyzed based on missing = failure analyses.
Time frame: Week 48
Cohort 1: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 24, Based on Missing = Excluded Analyses
The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 24 was analyzed based on missing = excluded analyses.
Time frame: Week 24
Cohort 1: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 48, Based on Missing = Excluded Analyses
The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 48 was analyzed based on missing = excluded analyses.
Time frame: Week 48
Cohort 1: Percentage of Participants With Plasma HIV-1 RNA < 400 Copies/mL at Week 24, Based on Missing = Excluded Analyses
The percentage of participants with HIV-1 RNA \< 400 copies/mL at Week 24 was analyzed based on missing = excluded analyses.
Time frame: Week 24
Cohort 1: Percentage of Participants With Plasma HIV-1 RNA < 400 Copies/mL at Week 48, Based on Missing = Excluded Analyses
The percentage of participants with HIV-1 RNA \< 400 copies/mL at Week 48 was analyzed based on missing = excluded analyses.
Time frame: Week 48
Cohort 2: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 24, Based on Missing = Excluded Analyses
The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 24 was analyzed based on missing = excluded analyses.
Time frame: Week 24
Cohort 2: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 48, Based on Missing = Excluded Analyses
The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 48 was analyzed based on missing = excluded analyses.
Time frame: Week 48
Cohort 2: Percentage of Participants With Plasma HIV-1 RNA < 400 Copies/mL at Week 24, Based on Missing = Excluded Analyses
The percentage of participants with HIV-1 RNA \< 400 copies/mL at Week 24 was analyzed based on missing = excluded analyses.
Time frame: Week 24
Cohort 2: Percentage of Participants With Plasma HIV-1 RNA < 400 Copies/mL at Week 48, Based on Missing = Excluded Analyses
The percentage of participants with HIV-1 RNA \< 400 copies/mL at Week 48 was analyzed based on missing = excluded analyses.
Time frame: Week 48
Cohort 3: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 24, Based on Missing = Excluded Analyses
The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 24 was analyzed based on missing = excluded analyses.
Time frame: Week 24
Cohort 3: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 48, Based on Missing = Excluded Analyses
The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 48 was analyzed based on missing = excluded analyses.
Time frame: Week 48
Cohort 1: Change From Baseline in Plasma log10 HIV-1 RNA at Week 24
Time frame: Baseline, Week 24
Cohort 1: Change From Baseline in Plasma log10 HIV-1 RNA at Week 48
Time frame: Baseline, Week 48
Cohort 1: Change From Baseline in Cluster of Differentiation (CD4+) Cell Count at Week 24
Time frame: Baseline, Week 24
Cohort 1: Change From Baseline in CD4+ Cell Count at Week 48
Time frame: Baseline, Week 48
Cohort 2: Change From Baseline in CD4+ Cell Count at Week 24
Time frame: Baseline, Week 24
Cohort 2: Change From Baseline in CD4+ Cell Count at Week 48
Time frame: Baseline, Week 48
Cohort 3: Change From Baseline in CD4+ Cell Count at Week 24
Time frame: Baseline, Week 24
Cohort 3: Change From Baseline in CD4+ Cell Count at Week 48
Time frame: Baseline, Week 48
Cohort 1: Change From Baseline in CD4+ Cell Percentage at Week 24
Time frame: Baseline, Week 24
Cohort 1: Change From Baseline in CD4+ Cell Percentage at Week 48
Time frame: Baseline, Week 48
Cohort 2: Change From Baseline in CD4+ Cell Percentage at Week 24
Time frame: Baseline, Week 24
Cohort 2: Change From Baseline in CD4+ Cell Percentage at Week 48
Time frame: Baseline, Week 48
Cohort 3: Change From Baseline in CD4+ Cell Percentage at Week 24
Time frame: Baseline, Week 24
Cohort 3: Change From Baseline in CD4+ Cell Percentage at Week 48
Time frame: Baseline, Week 48
Participants were enrolled at study sites in South Africa, Thailand, Uganda, United States of America, and Zimbabwe.
| Milestone | Cohort 1: Age 12 to < 18 Years and Weight ≥ 35 kg | Cohort 2: Age 6 to < 12 Years and Weight ≥ 25 kg | Cohort 3: Age ≥ 2 Years and Weight ≥ 14 to < 25 kg |
|---|---|---|---|
| Started | 50 | 52 | 27 |
| Completed | 48 | 51 | 27 |
| Not completed | 2 | 1 | 0 |
| Withdrew: Withdrew consent | 1 | 1 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 |
| Milestone | Cohort 1: Age 12 to < 18 Years and Weight ≥ 35 kg | Cohort 2: Age 6 to < 12 Years and Weight ≥ 25 kg | Cohort 3: Age ≥ 2 Years and Weight ≥ 14 to < 25 kg |
|---|---|---|---|
| Started | 48 | 50 | 27 |
| Completed | 44 | 49 | 27 |
| Not completed | 4 | 1 | 0 |
| Withdrew: Pregnancy | 1 | 0 | 0 |
| Withdrew: Investigator's discretion | 1 | 0 | 0 |
| Withdrew: Non-compliance with study drug | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 |
| Withdrew: Withdrew consent | 0 | 1 | 0 |
AUCtau is defined as concentration of drug over time (the area under the concentration versus time curve over the dosing interval).
| hr*ng/mL | Cohort 1: Age 12 to < 18 Years and Weight ≥ 35 kg |
|---|---|
| Pharmacokinetic (PK) Parameter: AUCtau of Elvitegravir (EVG) (Cohort 1) | 23840.1 ± 6076.15 |
AUCtau is defined as concentration of drug over time (the area under the concentration versus time curve over the dosing interval).
| hr*ng/mL | Cohort 2: Age 6 to < 12 Years and Weight ≥ 25 kg |
|---|---|
| PK Parameter: AUCtau of EVG (Cohort 2) | 33813.9 ± 19536.30 |
AUCtau is defined as concentration of drug over time (the area under the concentration versus time curve over the dosing interval).
| hr*ng/mL | Cohort 3: Age ≥ 2 Years and Weight ≥ 14 to < 25 kg |
|---|---|
| PK Parameter: AUCtau of EVG (Cohort 3) | 33245.6 ± 15499.22 |
AUClast is defined as the concentration of drug from time zero to the last observable concentration, area under the concentration time curve to last observation (AUClast).
| hr*ng/mL | Cohort 1: Age 12 to < 18 Years and Weight ≥ 35 kg |
|---|---|
| PK Parameter: AUClast of Tenofovir Alafenamide (TAF) (Cohort 1) | 188.9 ± 105.45 |
AUClast is defined as the concentration of drug from time zero to the last observable concentration.
| hr*ng/mL | Cohort 2: Age 6 to < 12 Years and Weight ≥ 25 kg |
|---|---|
| PK Parameter: AUClast of TAF (Cohort 2) | 332.9 ± 149.12 |
AUCtau is defined as concentration of drug over time (the area under the concentration versus time curve over the dosing interval).
| hr*ng/mL | Cohort 3: Age ≥ 2 Years and Weight ≥ 14 to < 25 kg |
|---|---|
| PK Parameter: AUCtau of TAF (Cohort 3) | 366.4 ± 144.91 |
Treatment-emergent adverse events (TEAEs) were defined as any AEs that begin or worsen on or after the start of study drug through 30 days after the last dose of study drug. The severity was graded based on the Gilead Sciences Grading Scale for Severity of Adverse Events. An AE that met one or more of the following outcomes was classified as serious: * Fatal * Life-threatening * Disabling/incapacitating * Results in hospitalization or prolongs a hospital stay * A congenital abnormality * Other important medical events may also be considered serious AEs if they may require medical or surgical intervention to prevent one of the outcomes listed above.
| percentage of participants | Cohort 1: Age 12 to < 18 Years and Weight ≥ 35 kg |
|---|---|
| Any TEAEs | 81.3 |
| SAEs | 8.3 |
TEAEs were defined as any AEs that begin or worsen on or after the start of study drug through 30 days after the last dose of study drug. The severity was graded based on the Gilead Sciences Grading Scale for Severity of Adverse Events. An AE that met one or more of the following outcomes was classified as serious: * Fatal * Life-threatening * Disabling/incapacitating * Results in hospitalization or prolongs a hospital stay * A congenital abnormality * Other important medical events may also be considered serious AEs if they may require medical or surgical intervention to prevent one of the outcomes listed above.
| percentage of participants | Cohort 2: Age 6 to < 12 Years and Weight ≥ 25 kg |
|---|---|
| Any TEAEs | 73.9 |
| SAEs | 0 |
TEAEs were defined as any AEs that begin or worsen on or after the start of study drug through 30 days after the last dose of study drug. The severity was graded based on the Gilead Sciences Grading Scale for Severity of Adverse Events. An AE that met one or more of the following outcomes was classified as serious: * Fatal * Life-threatening * Disabling/incapacitating * Results in hospitalization or prolongs a hospital stay * A congenital abnormality * Other important medical events may also be considered serious AEs if they may require medical or surgical intervention to prevent one of the outcomes listed above.
| percentage of participants | Cohort 3: Age ≥ 2 Years and Weight ≥ 14 to < 25 kg |
|---|---|
| Any TEAEs | 70.4 |
| SAEs | 3.7 |
Ctau is defined as the observed drug concentration at the end of the dosing interval.
| ng/mL | Cohort 1: Age 12 to < 18 Years and Weight ≥ 35 kg |
|---|---|
| EVG | 300.8 ± 243.69 |
| FTC | 102.4 ± 39.85 |
| TFV | 10.0 ± 2.13 |
| COBI | 25.0 ± 44.97 |
Ctau is defined as the observed drug concentration at the end of the dosing interval.
| ng/mL | Cohort 2: Age 6 to < 12 Years and Weight ≥ 25 kg |
|---|---|
| EVG | 370.0 ± 438.52 |
| FTC | 114.9 ± 27.70 |
| TFV | 15.1 ± 3.77 |
| COBI | 96.0 ± 162.01 |
Ctau is defined as the observed drug concentration at the end of the dosing interval.
| ng/mL | Cohort 3: Age ≥ 2 Years and Weight ≥ 14 to < 25 kg |
|---|---|
| EVG | 277.5 ± 223.43 |
| FTC | 82.5 ± 26.47 |
| TFV | 11.4 ± 2.65 |
| COBI | 23.0 ± 23.02 |
Cmax is defined as the maximum concentration of drug.
| ng/mL | Cohort 1: Age 12 to < 18 Years and Weight ≥ 35 kg |
|---|---|
| EVG | 2229.6 ± 427.93 |
| TAF | 166.8 ± 107.44 |
| FTC | 2265.0 ± 510.55 |
| TFV | 17.6 ± 4.18 |
| COBI | 1202.4 ± 421.21 |
Cmax is defined as the maximum concentration of drug.
| ng/mL | Cohort 2: Age 6 to < 12 Years and Weight ≥ 25 kg |
|---|---|
| EVG | 3055.2 ± 1180.90 |
| TAF | 313.3 ± 191.68 |
| FTC | 3397.4 ± 916.06 |
| TFV | 26.1 ± 5.43 |
| COBI | 2079.4 ± 970.81 |
Cmax is defined as the maximum concentration of drug.
| ng/mL | Cohort 3: Age ≥ 2 Years and Weight ≥ 14 to < 25 kg |
|---|---|
| EVG | 3297.2 ± 1720.38 |
| TAF | 286.6 ± 206.97 |
| FTC | 3007.4 ± 1138.10 |
| TFV | 19.6 ± 4.72 |
| COBI | 1525.5 ± 788.12 |
Apparent oral clearance (CL/F) is defined as the apparent clearance of the drug following oral administration.
| L/hr | Cohort 1: Age 12 to < 18 Years and Weight ≥ 35 kg |
|---|---|
| EVG | 6.7 ± 1.74 |
| TAF | 68.6 ± 52.64 |
CL/F is defined as the apparent clearance of the drug following oral administration.
| L/hr | Cohort 2: Age 6 to < 12 Years and Weight ≥ 25 kg |
|---|---|
| EVG | 6.3 ± 5.11 |
| TAF | 31.9 ± 11.21 |
CL/F is defined as the apparent clearance of the drug following oral administration.
| L/hr | Cohort 3: Age ≥ 2 Years and Weight ≥ 14 to < 25 kg |
|---|---|
| EVG | 3.4 ± 1.79 |
| TAF | 18.5 ± 6.27 |
Vz/F is defined as the apparent volume of distribution of the drug after oral administration.
| liters | Cohort 1: Age 12 to < 18 Years and Weight ≥ 35 kg |
|---|---|
| EVG | 60.5 ± 18.77 |
| TAF | 49.7 ± 32.54 |
Vz/F is defined as the apparent volume of distribution of the drug after oral administration.
| liters | Cohort 2: Age 6 to < 12 Years and Weight ≥ 25 kg |
|---|---|
| EVG | 46.8 ± 36.02 |
| TAF | 28.6 ± 25.74 |
Vz/F is defined as the apparent volume of distribution of the drug after oral administration.
| liters | Cohort 3: Age ≥ 2 Years and Weight ≥ 14 to < 25 kg |
|---|---|
| EVG | 28.5 ± 28.30 |
| TAF | 16.3 ± 11.07 |
AUCtau is defined as concentration of drug over time (the area under the concentration versus time curve over the dosing interval).
| hr*ng/mL | Cohort 1: Age 12 to < 18 Years and Weight ≥ 35 kg |
|---|---|
| FTC | 14424.4 ± 3452.88 |
| TFV | 287.6 ± 54.09 |
| COBI | 8240.8 ± 2972.94 |
AUCtau is defined as concentration of drug over time (the area under the concentration versus time curve over the dosing interval).
| hr*ng/mL | Cohort 2: Age 6 to < 12 Years and Weight ≥ 25 kg |
|---|---|
| FTC | 20629.2 ± 3906.01 |
| TFV | 440.2 ± 92.13 |
| COBI | 15890.7 ± 8208.78 |
AUCtau is defined as concentration of drug over time (the area under the concentration versus time curve over the dosing interval).
| hr*ng/mL | Cohort 3: Age ≥ 2 Years and Weight ≥ 14 to < 25 kg |
|---|---|
| FTC | 19468.1 ± 5635.74 |
| TFV | 334.9 ± 76.77 |
| COBI | 14485.2 ± 7166.10 |
The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 24 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
| percentage of participants | Cohort 1: Age 12 to < 18 Years and Weight ≥ 35 kg |
|---|---|
| Cohort 1: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 24, as Defined by the FDA Snapshot Analysis | 90.0 |
The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
| percentage of participants | Cohort 1: Age 12 to < 18 Years and Weight ≥ 35 kg |
|---|---|
| Cohort 1: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 48, as Defined by the FDA Snapshot Analysis | 92.0 |
The percentage of participants with HIV-1 RNA \< 400 Copies/mL at Week 24 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
| percentage of participants | Cohort 1: Age 12 to < 18 Years and Weight ≥ 35 kg |
|---|---|
| Cohort 1: Percentage of Participants With Plasma HIV-1 RNA < 400 Copies/mL at Week 24, as Defined by the FDA Snapshot Analysis | 94.0 |
The percentage of participants with HIV-1 RNA \< 400 Copies/mL at Weeks 24 and 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
| percentage of participants | Cohort 1: Age 12 to < 18 Years and Weight ≥ 35 kg |
|---|---|
| Cohort 1: Percentage of Participants With Plasma HIV-1 RNA < 400 Copies/mL at Week 48, as Defined by the FDA Snapshot Analysis | 94.0 |
The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 24 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
| percentage of participants | Cohort 2: Age 6 to < 12 Years and Weight ≥ 25 kg |
|---|---|
| Cohort 2: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 24, as Defined by the FDA Snapshot Analysis | 100.0 (93.2 to 100.0) |
The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
| percentage of participants | Cohort 2: Age 6 to < 12 Years and Weight ≥ 25 kg |
|---|---|
| Cohort 2: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 48, as Defined by the FDA Snapshot Analysis | 98.1 (89.7 to 100.0) |
The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 24 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
| percentage of participants | Cohort 3: Age ≥ 2 Years and Weight ≥ 14 to < 25 kg |
|---|---|
| Cohort 3: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 24, as Defined by the FDA Snapshot Analysis | 96.3 (81.0 to 99.9) |
The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
| percentage of participants | Cohort 3: Age ≥ 2 Years and Weight ≥ 14 to < 25 kg |
|---|---|
| Cohort 3: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 48, as Defined by the FDA Snapshot Analysis | 96.3 (81.0 to 99.9) |
The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 24 was analyzed based on missing = failure analyses.
| percentage of participants | Cohort 1: Age 12 to < 18 Years and Weight ≥ 35 kg |
|---|---|
| Cohort 1: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 24, Based on Missing = Failure Analyses | 90.0 (78.2 to 96.7) |
The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 48 was analyzed based on missing = failure analyses.
| percentage of participants | Cohort 1: Age 12 to < 18 Years and Weight ≥ 35 kg |
|---|---|
| Cohort 1: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 48, Based on Missing = Failure Analyses | 92.0 (80.8 to 97.8) |
The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 24 was analyzed based on missing = failure analyses.
| percentage of participants | Cohort 1: Age 12 to < 18 Years and Weight ≥ 35 kg |
|---|---|
| Cohort 1: Percentage of Participants With Plasma HIV-1 RNA < 400 Copies/mL at Week 24, Based on Missing = Failure Analyses | 94.0 |
The percentage of participants with HIV-1 RNA \< 400 copies/mL at Week 48 was analyzed based on missing = failure analyses.
| percentage of participants | Cohort 1: Age 12 to < 18 Years and Weight ≥ 35 kg |
|---|---|
| Cohort 1: Percentage of Participants With Plasma HIV-1 RNA < 400 Copies/mL at Week 48, Based on Missing = Failure Analyses | 94.0 |
The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 24 was analyzed based on missing = failure analyses.
| percentage of participants | Cohort 2: Age 6 to < 12 Years and Weight ≥ 25 kg |
|---|---|
| Cohort 2: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 24, Based on Missing = Failure Analyses | 100.0 (93.2 to 100.0) |
The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 48 was analyzed based on missing = failure analyses.
| percentage of participants | Cohort 2: Age 6 to < 12 Years and Weight ≥ 25 kg |
|---|---|
| Cohort 2: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 48, Based on Missing = Failure Analyses | 100.0 (93.2 to 100.0) |
The percentage of participants with HIV-1 RNA \< 400 copies/mL at Week 24 was analyzed based on missing = failure analyses.
| percentage of participants | Cohort 2: Age 6 to < 12 Years and Weight ≥ 25 kg |
|---|---|
| Cohort 2: Percentage of Participants With Plasma HIV-1 RNA < 400 Copies/mL at Week 24, Based on Missing = Failure Analyses | 100.0 |
The percentage of participants with HIV-1 RNA \< 400 copies/mL at Week 48 was analyzed based on missing = failure analyses.
| percentage of participants | Cohort 2: Age 6 to < 12 Years and Weight ≥ 25 kg |
|---|---|
| Cohort 2: Percentage of Participants With Plasma HIV-1 RNA < 400 Copies/mL at Week 48, Based on Missing = Failure Analyses | 100.0 |
The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 24 was analyzed based on missing = failure analyses.
| percentage of participants | Cohort 3: Age ≥ 2 Years and Weight ≥ 14 to < 25 kg |
|---|---|
| Cohort 3: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 24, Based on Missing = Failure Analyses | 96.3 (81.0 to 99.9) |
The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 48 was analyzed based on missing = failure analyses.
| percentage of participants | Cohort 3: Age ≥ 2 Years and Weight ≥ 14 to < 25 kg |
|---|---|
| Cohort 3: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 48, Based on Missing = Failure Analyses | 96.3 (81.0 to 99.9) |
The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 24 was analyzed based on missing = excluded analyses.
| percentage of participants | Cohort 1: Age 12 to < 18 Years and Weight ≥ 35 kg |
|---|---|
| Cohort 1: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 24, Based on Missing = Excluded Analyses | 93.8 (82.8 to 98.7) |
The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 48 was analyzed based on missing = excluded analyses.
| percentage of participants | Cohort 1: Age 12 to < 18 Years and Weight ≥ 35 kg |
|---|---|
| Cohort 1: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 48, Based on Missing = Excluded Analyses | 95.8 (85.7 to 99.5) |
The percentage of participants with HIV-1 RNA \< 400 copies/mL at Week 24 was analyzed based on missing = excluded analyses.
| percentage of participants | Cohort 1: Age 12 to < 18 Years and Weight ≥ 35 kg |
|---|---|
| Cohort 1: Percentage of Participants With Plasma HIV-1 RNA < 400 Copies/mL at Week 24, Based on Missing = Excluded Analyses | 97.9 |
The percentage of participants with HIV-1 RNA \< 400 copies/mL at Week 48 was analyzed based on missing = excluded analyses.
| percentage of participants | Cohort 1: Age 12 to < 18 Years and Weight ≥ 35 kg |
|---|---|
| Cohort 1: Percentage of Participants With Plasma HIV-1 RNA < 400 Copies/mL at Week 48, Based on Missing = Excluded Analyses | 97.9 |
The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 24 was analyzed based on missing = excluded analyses.
| percentage of participants | Cohort 2: Age 6 to < 12 Years and Weight ≥ 25 kg |
|---|---|
| Cohort 2: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 24, Based on Missing = Excluded Analyses | 100.0 (93.2 to 100.0) |
The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 48 was analyzed based on missing = excluded analyses.
| percentage of participants | Cohort 2: Age 6 to < 12 Years and Weight ≥ 25 kg |
|---|---|
| Cohort 2: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 48, Based on Missing = Excluded Analyses | 100.0 (93.2 to 100.0) |
The percentage of participants with HIV-1 RNA \< 400 copies/mL at Week 24 was analyzed based on missing = excluded analyses.
| percentage of participants | Cohort 2: Age 6 to < 12 Years and Weight ≥ 25 kg |
|---|---|
| Cohort 2: Percentage of Participants With Plasma HIV-1 RNA < 400 Copies/mL at Week 24, Based on Missing = Excluded Analyses | 100.0 |
The percentage of participants with HIV-1 RNA \< 400 copies/mL at Week 48 was analyzed based on missing = excluded analyses.
| percentage of participants | Cohort 2: Age 6 to < 12 Years and Weight ≥ 25 kg |
|---|---|
| Cohort 2: Percentage of Participants With Plasma HIV-1 RNA < 400 Copies/mL at Week 48, Based on Missing = Excluded Analyses | 100.0 |
The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 24 was analyzed based on missing = excluded analyses.
| percentage of participants | Cohort 3: Age ≥ 2 Years and Weight ≥ 14 to < 25 kg |
|---|---|
| Cohort 3: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 24, Based on Missing = Excluded Analyses | 96.3 (81.0 to 99.9) |
The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 48 was analyzed based on missing = excluded analyses.
| percentage of participants | Cohort 3: Age ≥ 2 Years and Weight ≥ 14 to < 25 kg |
|---|---|
| Cohort 3: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 48, Based on Missing = Excluded Analyses | 96.3 (81.0 to 99.9) |
| copies/mL | Cohort 1: Age 12 to < 18 Years and Weight ≥ 35 kg |
|---|---|
| Baseline | 4.62 ± 0.587 |
| Change at Week 24 | -3.25 ± 0.645 |
| copies/mL | Cohort 1: Age 12 to < 18 Years and Weight ≥ 35 kg |
|---|---|
| Baseline | 4.62 ± 0.587 |
| Change at Week 48 | -3.26 ± 0.712 |
| cells/μL | Cohort 1: Age 12 to < 18 Years and Weight ≥ 35 kg |
|---|---|
| Baseline | 471 ± 212.2 |
| Change at Week 24 | 191 ± 175.2 |
| cells/μL | Cohort 1: Age 12 to < 18 Years and Weight ≥ 35 kg |
|---|---|
| Baseline | 471 ± 212.2 |
| Change at Week 48 | 224 ± 170.3 |
| cells/μL | Cohort 2: Age 6 to < 12 Years and Weight ≥ 25 kg |
|---|---|
| Baseline | 961 ± 275.5 |
| Change at Week 24 | -118 ± 194.1 |
| cells/µL | Cohort 2: Age 6 to < 12 Years and Weight ≥ 25 kg |
|---|---|
| Baseline | 961 ± 275.5 |
| Change at Week 48 | -66 ± 203.6 |
| cells/μL | Cohort 3: Age ≥ 2 Years and Weight ≥ 14 to < 25 kg |
|---|---|
| Baseline | 1153 ± 459.9 |
| Change at Week 24 | -137 ± 278.3 |
| cells/µL | Cohort 3: Age ≥ 2 Years and Weight ≥ 14 to < 25 kg |
|---|---|
| Baseline | 1153 ± 459.9 |
| Change at Week 48 | -179 ± 319.2 |
| percentage of CD4+ cell | Cohort 1: Age 12 to < 18 Years and Weight ≥ 35 kg |
|---|---|
| Baseline | 23.6 ± 8.80 |
| Change at Week 24 | 7.7 ± 4.77 |
| percentage of CD4+ cell | Cohort 1: Age 12 to < 18 Years and Weight ≥ 35 kg |
|---|---|
| Baseline | 23.6 ± 8.80 |
| Change at Week 48 | 9.3 ± 5.19 |
| percentage of CD4+ cell | Cohort 2: Age 6 to < 12 Years and Weight ≥ 25 kg |
|---|---|
| Baseline | 38.2 ± 6.44 |
| Change at Week 24 | -0.8 ± 3.97 |
| percentage of CD4+ cell | Cohort 2: Age 6 to < 12 Years and Weight ≥ 25 kg |
|---|---|
| Baseline | 38.2 ± 6.44 |
| Change at Week 48 | -0.6 ± 4.37 |
| percentage of CD4+ cell | Cohort 3: Age ≥ 2 Years and Weight ≥ 14 to < 25 kg |
|---|---|
| Baseline | 35.9 ± 6.73 |
| Change at Week 24 | 0.0 ± 4.40 |
| percentage of CD4+ cell | Cohort 3: Age ≥ 2 Years and Weight ≥ 14 to < 25 kg |
|---|---|
| Baseline | 35.9 ± 6.73 |
| Change at Week 48 | 0.2 ± 3.78 |
Collected over Up to 583 Weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1: Age 12 to < 18 Years and Weight ≥ 35 kg | 1/50 (2%) | 10/50 (20%) | 47/50 (94%) |
| Cohort 2: Age 6 to < 12 Years and Weight ≥ 25 kg | 0/52 (0%) | 7/52 (13.5%) | 45/52 (86.5%) |
| Cohort 3: Age ≥ 2 Years and Weight ≥ 14 to < 25 kg | 0/27 (0%) | 1/27 (3.7%) | 25/27 (92.6%) |
| Event | Cohort 1: Age 12 to < 18 Years and Weight ≥ 35 kg | Cohort 2: Age 6 to < 12 Years and Weight ≥ 25 kg | Cohort 3: Age ≥ 2 Years and Weight ≥ 14 to < 25 kg |
|---|---|---|---|
| Suicide attemptPsychiatric disorders | 2/50 | 0/52 | 0/27 |
| PneumoniaInfections and infestations | 0/50 | 1/52 | 1/27 |
| UveitisEye disorders | 1/50 | 0/52 | 0/27 |
| Visual impairmentEye disorders | 1/50 | 0/52 | 0/27 |
| ConstipationGastrointestinal disorders | 1/50 | 0/52 | 0/27 |
| Abscess limbInfections and infestations | 1/50 | 0/52 | 0/27 |
| GastroenteritisInfections and infestations | 1/50 | 0/52 | 0/27 |
| Radius fractureInjury, poisoning and procedural complications | 1/50 | 0/52 | 0/27 |
| Road traffic accidentInjury, poisoning and procedural complications | 1/50 | 0/52 | 0/27 |
| Ulna fractureInjury, poisoning and procedural complications | 1/50 | 0/52 | 0/27 |
| Event | Cohort 1: Age 12 to < 18 Years and Weight ≥ 35 kg | Cohort 2: Age 6 to < 12 Years and Weight ≥ 25 kg | Cohort 3: Age ≥ 2 Years and Weight ≥ 14 to < 25 kg |
|---|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 20/50 | 14/52 | 14/27 |
| Respiratory tract infectionInfections and infestations | 19/50 | 11/52 | 4/27 |
| CoughRespiratory, thoracic and mediastinal disorders | 8/50 | 7/52 | 9/27 |
| NauseaGastrointestinal disorders | 15/50 | 2/52 | 0/27 |
| DiarrhoeaGastrointestinal disorders | 14/50 | 7/52 | 2/27 |
| MalariaInfections and infestations | 14/50 | 4/52 | 0/27 |
| HeadacheNervous system disorders | 14/50 | 8/52 | 1/27 |
| VomitingGastrointestinal disorders | 12/50 | 13/52 | 4/27 |
| Abdominal painGastrointestinal disorders | 11/50 | 10/52 | 0/27 |
| NasopharyngitisInfections and infestations | 3/50 | 2/52 | 5/27 |
The Safety Analysis Set included all participants who received at least 1 dose of study drug.
| Age, Continuous(years) | Cohort 1: Age 12 to < 18 Years and Weight ≥ 35 kg | Cohort 2: Age 6 to < 12 Years and Weight ≥ 25 kg | Cohort 3: Age ≥ 2 Years and Weight ≥ 14 to < 25 kg | Total |
|---|---|---|---|---|
| Mean | 15 ± 1.9 | 10 ± 1.2 | 6 ± 1.9 | 11 ± 3.7 |
| Age, Customized(Participants) | Cohort 1: Age 12 to < 18 Years and Weight ≥ 35 kg | Cohort 2: Age 6 to < 12 Years and Weight ≥ 25 kg | Cohort 3: Age ≥ 2 Years and Weight ≥ 14 to < 25 kg | Total |
|---|---|---|---|---|
| 2 to <6 Years | 0 | 0 | 11 | 11 |
| 6 to <12 Years | 0 | 52 | 16 | 68 |
| 12 to <18 Years | 50 | 0 | 0 | 50 |
| Sex: Female, Male(Participants) | Cohort 1: Age 12 to < 18 Years and Weight ≥ 35 kg | Cohort 2: Age 6 to < 12 Years and Weight ≥ 25 kg | Cohort 3: Age ≥ 2 Years and Weight ≥ 14 to < 25 kg | Total |
|---|---|---|---|---|
| Female | 28 | 30 | 17 | 75 |
| Male | 22 | 22 | 10 | 54 |
| Ethnicity (NIH/OMB)(Participants) | Cohort 1: Age 12 to < 18 Years and Weight ≥ 35 kg | Cohort 2: Age 6 to < 12 Years and Weight ≥ 25 kg | Cohort 3: Age ≥ 2 Years and Weight ≥ 14 to < 25 kg | Total |
|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 50 | 52 | 27 | 129 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Cohort 1: Age 12 to < 18 Years and Weight ≥ 35 kg | Cohort 2: Age 6 to < 12 Years and Weight ≥ 25 kg | Cohort 3: Age ≥ 2 Years and Weight ≥ 14 to < 25 kg | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 6 | 13 | 3 | 22 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 44 | 37 | 24 | 105 |
| White | 0 | 2 | 0 | 2 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Cohort 1: Age 12 to < 18 Years and Weight ≥ 35 kg | Cohort 2: Age 6 to < 12 Years and Weight ≥ 25 kg | Cohort 3: Age ≥ 2 Years and Weight ≥ 14 to < 25 kg | Total |
|---|---|---|---|---|
| South Africa | 3 | 0 | 13 | 16 |
| Thailand | 6 | 13 | 1 | 20 |
| Uganda | 30 | 27 | 8 | 65 |
| United States | 11 | 12 | 3 | 26 |
| Zimbabwe | 0 | 0 | 2 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at https://www.gileadclinicaltrials.com/transparency-policy#Commitment
Supporting information: Study protocol, Statistical analysis plan
Time frame: 18 months after study completion
Access criteria: A secured external environment with username, password, and RSA code.
Data sharing details ↗ · www.gileadclinicaltrials.com
Ran from May 2013 to primary completion in May 2020, 84 months.
Results were first posted in May 2021, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Elvitegravir · Cobicistat · Emtricitabine · Tenofovir alafenamide
Acquired Immunodeficiency Syndrome →